Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060645 · ClinicalTrials.gov registry record · Phase 1
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00060645 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 33 participants.
The verdict
NCT00060645, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
Interventions
- DRUG ridaforolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060645
The ClinicalTrials.gov registry entry for NCT00060645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ridaforolimus is the first listed.
NCT00060645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060645 about?
NCT00060645 is a clinical study titled "Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)". Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
What is the current status of trial NCT00060645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2003-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00060645?
The interventions under investigation include: ridaforolimus (DRUG).
Who is sponsoring clinical trial NCT00060645?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.